Sotatercept in Patients With Eisenmenger Syndrome

Patients with pulmonary arterial hypertension (PAH) experience long delays in diagnosis; however, little is known about the time between diagnosis and initiation of guideline-recommended optimal treatment. Immediate therapy is imperative for optimizing patient outcomes, as much of the pulmonary vasculature has already deteriorated by the time of diagnosis. 

Accurate resting oxygen consumption (rVO2) quantification is critical for Fick-derived cardiac output calculations. 

Pulmonary arterial hypertension (PAH) is a rare and progressive disease resulting in increased workload of the right ventricle (RV). Despite advances in therapies, PAH remains highly morbid from a progressive vasculopathy and RV failure.

Presented at PVRI 2026 Congress by James Klinger, Alpert Medical School of Brown University